MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced an exclusive United States agreement with LifeScan, Inc., a Johnson & Johnson (NYSE:JNJ) company, to distribute and co-market new blood glucose meters to be developed by LifeScan for Medtronic Diabetes patients. The new meters will be built using the OneTouch platform and will wirelessly transmit blood glucose test results to MiniMed Paradigm® insulin pumps and the Guardian® REAL-Time continuous glucose monitoring (CGM) system. The initial meter offering will be available to Medtronic’s U.S. patients early next calendar year, with planned meter enhancements to be introduced during the terms of the agreement.
